Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1906259rdf:typepubmed:Citationlld:pubmed
pubmed-article:1906259lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C1280551lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0324306lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0012133lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0376565lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:1906259lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:1906259pubmed:issue4lld:pubmed
pubmed-article:1906259pubmed:dateCreated1991-8-15lld:pubmed
pubmed-article:1906259pubmed:abstractTextThe pharmacokinetics of 2',3'-dideoxyinosine (ddI) were investigated in four adult male beagle dogs that received 15-min infusions of 20-, 50-, and 100-mg/kg doses in a randomized crossover study design. Plasma and urine samples were collected for 10 and 24 h, respectively, and assayed for ddI by high-performance liquid chromatographic methods. The mean maximum concentrations of drug in plasma at the end of 15-min infusions for the 20-, 50-, and 100-mg/kg doses were 33.3, 90.0, and 202 micrograms/ml, respectively. Area under the concentration-time curve data deviated significantly from linearity. The mean total clearance for the low dose (250 ml/min) was significantly greater than that for the high dose (190 ml/min). Renal clearance, which averaged between 98 and 116 ml/min, was dose independent. Renal clearance implied that nonrenal clearance decreased at the high dose (92 ml/min) when compared with that of the low dose (134 ml/min). The average urinary recovery of ddI for the high dose (51.2% of dose) was significantly greater than that for the low dose (45.8%). The volume of distribution at steady state averaged between 7.6 and 10.5 liters and decreased with increasing dose; however, it was not statistically significant. The mean half-life and mean residence time were invariant with respect to dose and averaged between 0.94 and 1.07 h and 0.61 and 0.71 h, respectively. In this dose range, ddI pharmacokinetics are dose dependent.lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:languageenglld:pubmed
pubmed-article:1906259pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:citationSubsetIMlld:pubmed
pubmed-article:1906259pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1906259pubmed:statusMEDLINElld:pubmed
pubmed-article:1906259pubmed:monthAprlld:pubmed
pubmed-article:1906259pubmed:issn0066-4804lld:pubmed
pubmed-article:1906259pubmed:authorpubmed-author:PittmanK AKAlld:pubmed
pubmed-article:1906259pubmed:authorpubmed-author:BarbhaiyaR...lld:pubmed
pubmed-article:1906259pubmed:authorpubmed-author:KaulSSlld:pubmed
pubmed-article:1906259pubmed:authorpubmed-author:DandekarK AKAlld:pubmed
pubmed-article:1906259pubmed:authorpubmed-author:KnuppC ACAlld:pubmed
pubmed-article:1906259pubmed:issnTypePrintlld:pubmed
pubmed-article:1906259pubmed:volume35lld:pubmed
pubmed-article:1906259pubmed:ownerNLMlld:pubmed
pubmed-article:1906259pubmed:authorsCompleteYlld:pubmed
pubmed-article:1906259pubmed:pagination610-4lld:pubmed
pubmed-article:1906259pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:meshHeadingpubmed-meshheading:1906259-...lld:pubmed
pubmed-article:1906259pubmed:year1991lld:pubmed
pubmed-article:1906259pubmed:articleTitlePharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.lld:pubmed
pubmed-article:1906259pubmed:affiliationDepartment of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Syracuse, New York 13221-4755.lld:pubmed
pubmed-article:1906259pubmed:publicationTypeJournal Articlelld:pubmed